Control Bionics (ASX: CBL) has signed a distribution agreement with PRC-Saltillo, a world leader in Augmentative and Alternative Communication (AAC) solutions, for the distribution of its NeuroNode® technology in the United States. The 2-year initial agreement provides Control Bionics with access to PRC-Saltillo’s established clinical support network and customer base, expanding market reach without the capital requirements of building direct sales infrastructure.
The agreement follows groundwork laid throughout 2025, during which PRC sales staff received training on NeuroNode technology, demonstration devices were deployed in market, and insurance funding was approved for PRC clients. This operational readiness positions the partnership for near-term commercial activity, though management expects a gradual sales ramp-up as PRC integrates the product into existing channels.
The deal represents the second major distribution partnership announced by Control Bionics in recent months, following the Tobii Dynavox agreement, and demonstrates execution on the company’s stated strategic priority of expanding NeuroNode availability through key distribution relationships.
What is Augmentative and Alternative Communication technology?
AAC technology encompasses devices and methods that help individuals with severe speech or language difficulties communicate. These solutions range from simple picture boards to sophisticated speech-generating devices controlled through various access methods.
The NeuroNode is designed to complement PRC’s existing AAC solutions by providing an additional access method for users who may have difficulty with traditional access technologies. By detecting very small muscle activations through surface electromyography (sEMG) technology, the NeuroNode enables individuals to control communication devices and other technology where alternative access methods may not be viable.
This technology addresses a critical gap. For individuals with conditions like advanced motor neurone disease or locked-in syndrome, even small voluntary movements may be preserved when other motor functions are severely compromised.
How the NeuroNode fits into PRC-Saltillo’s product ecosystem
PRC-Saltillo is widely recognised as a global leader in the AAC market, with a long history of delivering innovative communication solutions and clinical support to individuals with communication disabilities. The NeuroNode integration provides an additional access modality within these existing systems, complementing rather than replacing established methods.
Control Bionics brings more than 20 years of experience in the development and commercialisation of sEMG-based assistive technology. The NeuroNode represents the company’s core patented technology: a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle, captured as EMG output and transmitted wirelessly to a personal computer, enabling speech and other computer-controlled functions.
The technology integrates three distinct control modalities:
- Touch control for users with preserved hand function
- Eye gaze control enabling cursor movement through eye tracking
- NeuroNode EMG control functioning like a mouse button activated by muscle signals
This multi-modal approach allows users to leverage whichever access method remains most functional, yielding unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.
Join thousands of readers who start here
Our best articles, sent straight to your inbox. You can unsubscribe anytime.
Partnership readiness and market preparation
The operational foundation established during 2025 reduces execution risk typically associated with new distribution partnerships. PRC-Saltillo’s sales teams completed NeuroNode training before the formal agreement, demonstration units underwent real-world testing, and insurance funding was approved for PRC clients to access the NeuroNode.
| Milestone | Status |
|---|---|
| PRC sales staff training | Completed |
| Demonstration devices deployed | In market |
| Insurance funding for clients | Already approved |
| Agreement term | 2 years (initial) |
This preparation contrasts with partnerships where product integration and market education occur after signing. The validation of insurance funding pathways particularly matters in the assistive technology market, where reimbursement approval can create significant commercialisation delays.
CEO Jeremy Steele noted the company expects sales to ramp up gradually as partners onboard, continue to train teams and integrate the product into their sales channels, signalling realistic near-term expectations rather than immediate revenue transformation.
CEO commentary on strategic positioning
Management Perspective
“PRC is a world leader in AAC solutions, and we are very pleased to formalise this distribution agreement for the NeuroNode in the United States. PRC has been working with the NeuroNode throughout 2025, with trained sales staff, devices in market for demonstrations, and funding already approved for clients, which gives us confidence in their ability to scale access to the technology,” said Jeremy Steele, CEO and Managing Director.
Steele positioned the agreement as a further demonstration of one of Control Bionics’ five key strategic priorities of expanding NeuroNode sales across key regions with key strategic distribution relationships, adding to the recently announced distribution partnership with Tobii Dynavox.
The CEO emphasised the agreement “reinforces the growing recognition of sEMG-based access as a valuable complement to existing AAC solutions,” suggesting broader market acceptance of the technology beyond individual partnership wins.
Enjoyed this article?
We publish high-impact stories like this a few times a week. No spam.
Strategic outlook and investment thesis
The distribution agreement marks the second major distribution partnership announced by the company, validating its capital-efficient approach to US market expansion. Rather than building direct sales infrastructure requiring significant upfront investment, Control Bionics leverages established distribution channels with existing customer relationships and clinical support networks.
PRC-Saltillo’s global presence and reputation in the AAC market provides Control Bionics with credible market validation. The partnership structure offers multiple strategic advantages:
- Access to PRC’s established AAC customer base and clinical support network
- Pre-trained sales force ready to promote NeuroNode
- Insurance funding pathways already approved
- Complements existing Tobii Dynavox partnership
While commercial terms remain confidential, the 2-year initial term provides sufficient runway for market penetration and revenue generation assessment. The gradual sales ramp-up expectation acknowledged by management reflects realistic commercialisation timelines in the assistive technology sector, where clinical adoption and reimbursement processes create natural scaling periods.
For investors, the agreement demonstrates Control Bionics’ ability to secure partnerships with recognised industry leaders, suggesting the NeuroNode’s technical capabilities and commercial proposition resonate with established market participants. With operations spanning North America, Australia, Singapore and Japan, the company’s geographic footprint continues expanding through these strategic relationships rather than capital-intensive direct expansion.
The partnership-led growth strategy appears to be gaining traction, with two significant distribution agreements now in place and market preparation activities suggesting potential for near-term revenue contribution as the NeuroNode integrates into partner sales channels.
Want more Biotech breakthroughs like this?
Control Bionics’ partnership with PRC-Saltillo demonstrates how strategic distribution agreements can accelerate market access for innovative medical technologies. For investors tracking the ASX Biotech and Healthcare sectors, developments like these often signal inflection points in commercialisation timelines—but they’re easy to miss without dedicated sector coverage.
The Big News Blast from StockWire X delivers breaking ASX news and comprehensive analysis across non-resource sectors including Biotech, Healthcare, Tech, Finance and Industrials—completely FREE. Trusted by over 20,000+ active subscribers, these alerts provide the context needed to identify emerging opportunities before broader market recognition. Click the “Free Alerts” button in the site menu to receive these market-moving updates directly to your inbox.